Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights

Receptor tyrosine kinases (RTKs) inhibitors’ activity in advanced osteosarcoma is significant but short-lived. To prevent or at least delay drug resistance, we explored a vertical inhibition by combining drugs acting at different levels of the RTK pathways (pazopanib + trametinib). We studied pazopa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiabotto, Giulia, Grignani, Giovanni, Todorovic, Maja, Martin, Valentina, Centomo, Maria Laura, Prola, Elisa, Giordano, Giorgia, Merlini, Alessandra, Miglio, Umberto, Berrino, Enrico, Napione, Lucia, Isella, Claudio, Capozzi, Federica, Basiricò, Marco, Marsero, Cristina, Gerardi, Ilaria, Venesio, Tiziana, Sangiolo, Dario, Aglietta, Massimo, D’Ambrosio, Lorenzo, Pignochino, Ymera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352822/
https://www.ncbi.nlm.nih.gov/pubmed/32531992
http://dx.doi.org/10.3390/cancers12061519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352822/
https://www.ncbi.nlm.nih.gov/pubmed/32531992
http://dx.doi.org/10.3390/cancers12061519

Ejemplares similares